We report here the discovery, isolation, and chemical and preliminary 
7-O-malonyl Macrolactin

Introduction
The spread of resistance to antibiotics undermines the therapeutic utility of anti-infective drugs in current clinical use (1) . For example, Staphylococcus aureus, a major cause of community and hospital-acquired infections, has developed resistance to most classes of antibiotics. Methicillin-resistant S.
aureus (MRSA) strains appeared in the hospital environment after introduction of the semi-synthetic penicillin, methicillin, leaving vancomycin as the last line of defence for MRSA treatment (7) . Vancomycin-intermediately-susceptible S.
aureus were first isolated in 1997 in Japan (12) and later in other countries (8) .
With the recent appearance of vancomycin-resistant clinical isolates (32, 36, 38) , no antibiotic class is effective against multi-resistant S. aureus infections.
The increase of vancomycin-resistant enterococci (VRE), important agents of nosocomial infections, is another cause of great concern (2, 3, 19, 27) . Therapy options for multi-resistant Gram-negative opportunistic bacterial pathogens are also diminishing. Such bacteria, like Pseudomonas aeruginosa and Burkholderia cepacia (6) , are common environmental organisms and opportunistic pathogens having the capacity to infect essentially all tissues of patients with compromised host defences (21) .
Compounding the problem of genetically-determined transmissible antibiotic resistance is the development of phenotypically-resistant, often slowgrowing, forms in chronic bacterial infections. These may take the form of biofilm microbes or small colony variants (SCV; 13, reviewed in 15), are known for both Gram positive and Gram negative pathogens, and are usually associated with a worsening of the disease prognosis.
Thus, new antibiotics and therapy options are urgently needed to improve the management of bacterial infections (29, 35) , and a major challenge is to find drugs that act against SCVs and/or bacteria growing in biofilms.
In this study, we report the discovery and preliminary characterization of Hannover (Germany). The B. cepacia WT strain 139 was isolated from a bronchoalveolar lavage and its SCV form 141 from a blood sample from the same patient. P. aeruginosa WT strain 134 and its SCV form 137 were isolated from the same respiratory tract specimen. The clonal identities of the SCVs and WTs were determined by pulsed-field gel electrophoresis, as previously described (13, 14) .
The antibiotic producing bacterium, ICBB 1582, was isolated from a soil sample obtained from a farmyard at Takalar, South Sulawesi Province, Indonesia, in April 2000. The strain was deposited in the DSMZ under the accession number DSM 16696. Biochemical and phenotypic characterisations were made using Api 20E and 50CH kits (Biomerieux, Marcy l'Etoile, France). 16S rRNA sequence determination and analysis, performed as previously described (40) , identified the organism as a Bacillus subtilis strain. All organisms were maintained in glycerol broth at -80°C.
Bacteria were cultivated overnight at 37°C on Luria-Bertani (LB) agar, except staphylococci and enterococci, which were grown on Columbia blood agar (BD, NJ, USA). Yeast strains were grown in DSM M186 medium Antibiotics. Erythromycin (ERY), Vancomycin (VAN), Ampicillin (AMP), Gentamicin (GEN) and Miconazole (MCZ) were obtained from Sigma-Aldrich (Schnelldorf, Germany). Stock solutions, 10 mg/ml, were freshly prepared in sterile distilled water, except for erythromycin, which was prepared in ethanol.
Erythromycin discs were obtained from A/S Rosco (Taastrup, Denmark) and contained 78 µg of diffusible antibiotic. Vancomycin and Ampicillin discs were obtained from BBL (NJ, USA) and contained respectively, 30 and 10 µg/disc.
Cultivation of the Bacillus subtilis DSM 16696 strain and extraction of secondary metabolites.
The preparation and recovery of secondary metabolites was carried out essentially as described by Sasse et al. (31) . Briefly, this involved the inoculation of 500 ml Erlenmeyer flasks containing 200 ml of medium described above with 0.5 ml quantities of an overnight culture of B. at 37°C, samples were diluted 1:1000 in warmed drug-free MHB to dilute out the antibiotic and incubated further at 37°C. Viability counts were made before exposure, immediately after dilution (0 h), and then hourly, by plating on LB agar plates as described above. The SME was defined by the relationship SME = Ts -C, where Ts is the time it takes for cultures exposed to sub-MICs to increase 1 log 10 unit above the counts observed immediately after antibiotic removal by dilution, and C is the corresponding time for the unexposed control. culture medium were used as controls: no effect of these solutions on cell growth was observed. Morphological changes in cells after exposure to the compounds for 1, 2 and 5 days were assessed by phase-contrast microscopy.
Cell counts after 5 days of exposure were also made using the CyQUANT cell proliferation assay (Molecular Probes, Eugene, USA), a highly sensitive, fluorescence-based microplate assay for determining numbers of cultured cells (17) , that employs CyQUANT dye, which produces a large fluorescence enhancement upon binding to cellular nucleic acids that can be measured using Table 2 ). All macrolactins showed good inhibition activity against both methicillin sensitive and MRSA but, whereas MMA and SMA also inhibited VRE, unsubstituted macrolactin A did not. However, the inhibition zones observed with the staphylococcal test strains were straight turbid, rather than clear, suggesting a growth inhibition rather than a bactericidal activity. To rule out the possibility of the turbidity results from the development of resistant variants, the small colonies developing in the inhibition zones were purified and re-tested for sensitivity. In all cases, they gave turbid inhibition zones, confirming that the macrolactins inhibit growth rather than kill (data not shown).
These qualitative experiments were subsequently confirmed by quantitative determination of MIC values, the antibiotic concentrations that totally prevent microbial growth in liquid cultures (Table 3 ). In fact, the MICs of MMA for staphylococci and enterococci were higher than 128 µg/ml, but, a strong inhibition of growth of both types of organism was observed at much lower concentrations. We therefore determined the lowest concentrations of the new compound that resulted in 50% inhibition of bacterial growth, the MRC (minimal restrictive concentration). The MRCs were between 1 and 64 µg/ml for the S. aureus reference strains and for the MRSA strains; and between 0.06 and 4 µg/ml for E. faecalis ATCC strain 29212 and the clinical isolates VRAS E305 and VRAR E315 (Table 3) . No changes in the end points occurred when the incubation was extended to 48 h, which shows that the bacteria inhibited by the drugs do not re-initiate growth (data not shown). The liquid growth test also confirmed that MMA and SMA exhibited higher activities than MA, against MRSA and VRE, suggesting the importance of substituents on the C-7 for the biological activity of this group of compounds (data not shown).
MMA was not active against the majority of the gram-negative isolates tested (data not shown). Interestingly, however, a small colony variant of B.
cepacia, but not the parental normal colony type, was inhibited, as was a Candida krusei strain, but not other Candida strains tested (Table 3) .
Long term inhibition of staphylococci and enterococci at MMA sub-
MICs. To investigate the growth inhibition effect of 7-O-malonyl macrolactin
A, time courses of the effects on bacterial viability of antibiotic at several sub-MIC values were followed (Fig. 2) . MMA at 1 µg/ml, rapidly reduced the counted number of viable cells of the methicillin-susceptible S. aureus strain by almost 2 orders of magnitude over the first two hours of exposure. Over the next 6 hours, bacterial multiplication occurred at the same rate as that of the nontreated control; though levels remained about one log lower than those of the controls over the 24 hours period of the experiment. In the case of the MRSA 3 strain, no significant reduction in counts of viable cells occurred, but no significant growth was observed either, and by the end of the experiment there was a difference of >2 logs in the number of viable cells of the treated and control cultures. In the case of the E. faecalis ATCC strain 12912, the reduction in number of viable cells observed, ca. 50%, was less than that seen with the S. aureus reference strain, but otherwise the picture was similar. Also, MMA had an inhibitory effect on the VRAR E. faecium strain E 315 similar to that on the MRSA strain, namely complete inhibition of growth. Essentially, the same patterns of viable cell numbers were seen with both sub-inhibitory concentrations of antibiotic, 4 and 16 µg/ml. Thus, interestingly, MMA was bacteriostatic for the antibiotic-resistant strains tested in liquid cultures but less inhibitory for the sensitive ones, though the sample is too small to generalize.
MMA induces significant cellular damage at sub-MICs. The PAE and sub-MICs effect (SME), the time taken to repair and recover from antibiotic damage, are important properties of antibiotics which reflect the degree of such damage inflicted by antibiotics, at supra-MICs and sub-MICs, respectively (5, 25) . The SMEs for the VRAR E. faecium strain E 315 and MRSA strain 3 after 1 h of exposure to 16 µg/m MMA were 2.31 h and 0.42 h, respectively, indicating that the compound induced significant damage, particularly in enterococci, at sub-MIC concentrations.
MMA inhibits separation of daughter cells. MMA-treated cells of E.
faecium VRAR E315 and MRSA 3 were examined by electron microscopy in order to obtain ultrastructural information about the damage caused. Sub-MICs of MMA had very marked effects on cell division and separation of daughter cells was severely inhibited through incomplete septum-formation ( Fig. 3 and 4) .
Treated cells of MRSA 3 were larger than controls, and approximately 60% were observed in packets of non-separated cells (data not shown), in which multiple asymmetric initiation points of septum formation were visible (Fig. 3 d, e and f). Similarly, treated E. faecium VRAR E315 showed chains of nonseparated cells, in which several symmetric initiations of cell division are evident (Fig. 4 d, e and f) . Moreover, treated cells of E. faecium had a smooth appearance whereas untreated cells had rough surfaces (Fig. 4 c and e) . SMA, but not MA, induced similar morphological alterations in both MRSA and VRE, but to a lesser extent (data not shown).
MMA exhibits weak cytotoxicity. Macrolactin A has previously been reported to exhibit cytotoxic and antiviral activities (10) and, as described above, MMA exhibited weak activity towards a Candida krusei strain. Possible activity of MMA towards mammalian cells was therefore assessed with L929 mouse fibroblasts and HeLa human epithelial cells. As can be seen in Fig. 5, all three macrolactins inhibit the growth of L929 mouse fibroblasts, with MA being the most active, which suggests that eukaryotic cytotoxicity may be modulated by varying the C-7 substituent. 7-O-malonyl macrolactin A was less inhibitory for the human than the mouse cells tested: quantitation of the cytotoxic effect by means of the CyQuant assay revealed that MMA partially inhibited the proliferation of HeLa cells at 31.25 µg/ml and totally at 62.5 µg/ml (Fig. 5) . The anti-proliferative effect of the macrolactins was reflected in a change in cell morphology to rounded cells.
DISCUSSION
Macrolactins are macrolides containing three separate diene structure elements in a 24-membered lactone ring (10), previously reported to be produced by a Bacillus sp., an unclassifiable marine bacterium, and an Actinomadura sp. (10, 16, 18, 23) . Six macrolactins were first described in 1989 by Gustafson et al. Another property of MMA of clinical relevance is its sub-MICs effect (SME), which reflects the degree of antibiotic-inflicted bacteria, because viable but damaged bacteria are more susceptible to clearence (25) . The SMEs for the vancomycin-and ampicillin-resistant E. faecium strain E 315 and methicillin- compounds that inhibit the cell wall synthesis, such as penicillins and compound P, the active principle of crude tea extract. MRSA and S. aureus grown in the presence of such compounds produce a thickened cell wall (9, 11) . Abnormal morphology and the appearance of amorphous material on the surface of glycopeptide-treated bacteria were also described for S. aureus and enterococci (20, 30, 39) . The mechanism by which 7-O-malonyl macrolactin A induces morphological changes is interesting because pseudo-multicellular clusters are unable to produce daughter cells and, as a consequence, should have a reduced ability to disseminate, and therefore be less virulent. The morphological alterations induced by MMA were not a unique property of this new compound, since they were also observed for the SMA. Since 7-O-malonyl-and-succynilmacrolactins analysed in this study showed superior antibacterial activity and lower cytotoxicity in comparison with macrolactin A, this indicates an important role of the C-7 residue in the biological activities of these compounds.
In conclusion, in this study we have described a new variant of macrolactin A, 7-O-malonyl macrolactin A, and showed it to inhibit the growth of MRSA, VRE and a SCV of B. cepacia. Together with 7-O-succynil macrolactin A, it would see to hold promise for the development of new drugs against these clinically problematic microbial pathogens. We have also provided evidence for a tentative target in cell wall biosynthesis, and this may ultimately lead to the identification of a new target for antimicrobial drug discovery programmes.
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